November 21, 2011
Drugmakers Novartis AG and Mylan Inc. have settled patent litigation over Mylan's bid to produce a generic version of Novartis' estrogen therapy drug Vivelle-Dot, which will allow the generic to be manufactured, Mylan announced Monday.
February 24, 2011
Units of Novartis AG and Hisamitsu Pharmaceutical Co. Inc. accused Mylan Inc. of infringing two of their patents by seeking to market a generic estradiol transdermal system in a pair of lawsuits filed this week.